# US 2022/0035179 A1 · Methods and devices for reducing myopia in children

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0035179 A1
- Document ID: US20220035179A1
- Status: Published application
- Kind: A1
- Application number: 17/259,779
- Filed: 2019-07-12
- Published: 2022-02-03
- Earliest claimed: 2018-07-12
- Assignees: SightGlass Vision, Inc.
- Applicants: Sightglass Vision, Inc.
- Inventors: Joseph Michael Rappon; Thomas W. Chalberg, Jr.; Vanessa Anne Tasso-Pinas, I; Yufen Chung; Peter Hones
- Web page: https://patentgrep.com/patent/US20220035179A1

## CPC

- G02C 7/061: {Spectacle lenses with progressively varying focal power}
- G02C 7/022: {Ophthalmic lenses having special refractive features achieved by special materials or material structures (G02C7/049 takes precedence)}
- G02C 7/16: Shades; shields; Obturators, e.g. with pinhole, with slot {(G02C5/003 takes precedence)}
- G02C 2202/24: Myopia progression prevention
- G02C: SPECTACLES; SUNGLASSES OR GOGGLES INSOFAR AS THEY HAVE THE SAME FEATURES AS SPECTACLES; CONTACT LENSES (trial frames for testing the eyes A61B3/04; goggles or eyeshields not having the same features as spectacles A61F9/00)

## Abstract

Methods and devices for treating a human child having myopia are disclosed. For example, a human child having myopia can be treated by wearing spectacles having one or two myopia control spectacle lenses.

## Claims

### Claim 1

A method for reducing progression of myopia in a human child having, or suspected of having, myopia, the method comprising:
identifying the human child having, or suspected of having, myopia; and
treating the human child with spectacles comprising at least one myopia control spectacle lens, wherein said myopia control spectacle lens provides normal visual acuity to the human child when viewed through a central region of the lens and reduced visual acuity for the when viewed through a peripheral region of the lens, and wherein said myopia control spectacle lens reduces myopia progression in the human child by 0.4 D or more after three years of treatment compared to a control group.

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The method of claim 1, wherein the reduced visual acuity is provided by a dot pattern in the peripheral region of the lens.

### Claim at position 4

4-5. (canceled)

### Claim 6 (depends on 1)

The method of claim 1, wherein treating the human child comprises treating both of the human child's eyes with corresponding myopia control spectacle lenses.

### Claim 7

(canceled)

### Claim 8 (depends on 1)

The method of claim 1, wherein, at the time of the identifying, the human child is younger than 12 years old.

### Claim at position 8

9-10. (canceled)

### Claim 11 (depends on 8)

The method of claim 8, wherein, at the time of the identifying, the human child is 6 to 10 years old.

### Claim at position 10

12-13. (canceled)

### Claim 14 (depends on 1)

The method of claim 1, wherein the myopia control spectacle lens comprises (i) a clear center, and (ii) a surrounding annular region, both (i) and (ii) substantially centered on a lens axis, the clear aperture corresponding to the central region and the annular region corresponding to the peripheral region and comprising one or more features that reduce the visual acuity for the corresponding eye.

### Claim 15 (depends on 14)

The method as in of claim 14, wherein the one or more features comprises a plurality of spaced apart scattering centers sized and shaped to scatter incident light.

### Claim 16 (depends on 15)

The method of claim 15, wherein the scattering centers are formed on a surface of the myopia control spectacle lens.

### Claim 17

(canceled)

### Claim 18 (depends on 15)

The method of claim 15, wherein the scattering centers have a diameter of 0.2 mm or less.

### Claim at position 16

19-20. (canceled)

### Claim 21 (depends on 15)

The method of claim 15, wherein, in the annular region, the scattering centers have an average density in a range from 2 to 5 per mm2.

### Claim at position 18

22-23. (canceled)

### Claim 24 (depends on 15)

The method as in claim 15, wherein the scattering centers are arranged in a pattern that includes a random variation in spacing between adjacent dots and/or a random variation in dot size.

### Claim 25 (depends on 24)

The method of claim 24, wherein the scattering centers are positioned relative to a regular array of lattice sites, wherein each scattering center is displaced in at least one dimension from a corresponding one of the lattice sites by an amount equal to or less than a jitter amplitude, the jitter amplitude being a fraction of the distance between adjacent lattice sites.

### Claim 26 (depends on 25)

The method of claim 25, wherein the jitter amplitude is 0.5 or less.

### Claim at position 22

27-30. (canceled)

### Claim 31 (depends on 14)

The method of claim 14, wherein the annular region corresponds to an area of 50% or more of the lens surface.

### Claim at position 24

32-36. (canceled)

### Claim 37 (depends on 1)

The method of claim 1, wherein the myopia control spectacle lens has optical power to correct the human's on-axis vision to 20/20 or better through the central region, and, corrects the human's vision to 20/25 or better through the peripheral region.

### Claim 38 (depends on 1)

The method of claim 1, wherein the child, prior to said treatment, has a spherical equivalent refractive error between −0.75 diopters and −4.50 diopters in at least one eye.

### Claim at position 27

39-40. (canceled)

### Claim 41 (depends on 1)

The method of claim 1, wherein said spectacles reduce myopia progression by at least 0.20 mm as measured by axial length change from baseline.

### Claim at position 29

42-43. (canceled)

### Claim 44 (depends on 1)

The method of claim 1, wherein said spectacles reduce myopia progression by at least 0.46 D as measured by autorefraction change from baseline.

### Claim 45 (depends on 1)

The method of claim 1, wherein said treatment comprises wearing said spectacles for at least 6 hours per day.

### Claim 46 (depends on 1)

The method of claim 1, wherein said treatment comprises using said spectacles for at least 12 months.

### Claim at position 33

47-50. (canceled)

### Claim 51 (depends on 1)

The method of claim 1, wherein said myopia control spectacle lens is made from polycarbonate or a urethane-based monomer.

### Claim 52 (depends on 1)

The method of claim 1, wherein said child has a genetic pre-disposition for myopia progression.

### Claim 53

(canceled)

### Claim 54 (depends on 1)

The method of claim 1, wherein said child is less than 8 years old when initiating therapy with said spectacles, and said reduction in myopia progression is greater than 0.20 D after 3 years.

### Claim 55 (depends on 1)

The method of claim 1, wherein said child is less than 8 years old when initiating therapy with said spectacles, and said reduction in myopia progression is greater than 15% after 3 years.

### Claim 56

Spectacles for reducing progression of myopia in a human child, the spectacles comprising at least one myopia control spectacle lens comprising a single vision region and a myopia control region, wherein the myopia control spectacle lens reduces myopia progression in the human child by 0.4 D or more after three years of treatment compared to a control group.

### Claim at position 40

57-75. (canceled)
